Basic Information

Gene symbol STAT3 Synonyms ADMIO, ADMIO1, APRF, HIES Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description signal transducer and activator of transcription 3

GTO ID GTC3542
Trial ID NCT05986240
Disease Myelodysplastic Syndrome
Altered gene STAT3
Therapeutic/Target gene Target gene
TherapyASO
Treatment ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx
PhasePhase1
Recruitment statusRecruiting
TitleA Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
Year2024
CountryUnited States
Company sponsorMontefiore Medical Center
Other ID(s)2022-14320|R01FD007836-01
Vector information
VectorNo vector was used

Clinical Result

Cohort1: Danvatirsen_dose level1
Administration route intravenous infusion
Dosage Danvatirsen, 1mg/kg, C1D1, C1D3, C1D5, followed weekly for 3 weeks
Age Adult, Older_Adult
Cohort2: Danvatirsen_dose level2
Administration route intravenous infusion
Dosage Danvatirsen, 2mg/kg, C1D1, C1D3, C1D5, followed weekly for 3 weeks
Age Adult, Older_Adult
Cohort3: Danvatirsen_dose level3
Administration route intravenous infusion
Dosage Danvatirsen, 3mg/kg, C1D1, C1D3, C1D5, followed weekly for 3 weeks
Age Adult, Older_Adult
Cohort4: Danvatirsen_Venetoclax
Administration route intravenous infusion
Dosage Danvatirsen|Venetoclax, 400 mg, daily for 28 days per cycle
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph